Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27145456 | 1.00 | EGFR (0.34) | EGFRPIK3CAMKNK2NR1I2PSEN1 | |
| SCHEMBL24478325 | 1.00 | EGFR (0.34) | EGFRPIK3CAMKNK2NR1I2PSEN1 | |
| SCHEMBL28726607 | 0.89 | EGFR (0.39) | EGFRPIK3CAPSEN1PSEN2APH1B | |
| SCHEMBL29481215 | 0.89 | EGFR (0.39) | EGFRPIK3CAPSEN1PSEN2APH1B | |
| SCHEMBL28726604 | 0.89 | EGFR (0.39) | EGFRPIK3CAPSEN1PSEN2APH1B | |
| SCHEMBL29631228 | 0.85 | MKNK2 (0.36) | EGFRPIK3CAMKNK2 | |
| SCHEMBL24478319 | 0.85 | MKNK2 (0.36) | EGFRPIK3CAMKNK2 | |
| SCHEMBL29631233 | 0.83 | USP2 (0.35) | EGFRMKNK2RPS6KB1 | |
| SCHEMBL24478400 | 0.83 | USP2 (0.35) | EGFRMKNK2RPS6KB1 | |
| SCHEMBL28726631 | 0.81 | EGFR (0.39) | EGFRPIK3CAPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116601149-A | Aminoquinazoline derivatives as P2X3 inhibitors | 奇斯药制品公司 | 2023-08-15 | — | — | CN | claimed |
| US-20240025880-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025880-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | EGFR 2409/4885PIK3CA 627/4885MKNK2 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.